<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=901475309917735&ev=PageView&noscript=1" />


Seishi Baba, Parliamentary Vice-Minister of Health, Labor and Welfare, Japan

Seishi Baba


  • Mar. 1983 - Graduated from Kumamoto prefectural Kumamoto Technical High School 


  • Aug. 2016 - Parliamentary Vice-Minister of Health, Labour and Welfare (Reshuffled Third Abe Cabinet) 
  • Jan. 2016 - Director, Committee on Rules and Administration, House of Councillors (HC) 
  • Nov. 2015 - Deputy Chairman, Diet Affair Committee, Liberal Democratic Party (LDP); Deputy Director, Fisheries Division, LDP; Deputy Director, Local Organization and Local Assembly Member Division 
  • Jul. 2015 - Director, Special Committee on Legislation for Peace and Security of Our Nation and International Community, HC 
  • Oct. 2014 - Director, Committee on Budget, HC 
  • Sept. 2014 - Deputy Director, Agriculture and Forestry Division, LDP
  • Nov. 2013 - Deputy Chairman, Committee on Organizations Involved with Agriculture, Forestry, and Fisheries, Party and Campaign Headquarters, LDP 
  • Oct. 2013 - Member, Committee on Audit, HC; Member, Special Committee on Disasters, HC 
  • Aug. 2013 - Member, Committee on Agriculture, Forestry, and Fisheries, HC 
  • Jul. 2013 - Elected to the HC in the 23 rd General Election 
  • Jun. 2011 - Deputy Chairman, National Association of Chairpersons of Prefectural Assemblies 
  • May 2011 - President, Kumamoto Prefectural Assembly 
  • May 2007 - Vice-President, Kumamoto Prefectural Assembly 
  • Dec. 1997 - Re-elected to the Kumamoto Prefectural Assembly for the fifth consecutive term
  • Apr. 1991 - Elected to the Kumamoto Prefectural Assembly for the second consecutive term


Philippe Fauchet, OBE, President & Representative Director, GlaxoSmithKline K.K.

Philippe Fauchet

Philippe Fauchet joined GlaxoSmithKline K.K. as President & Representative Director in January 2010. He is a member of the Pharmaceutical Operations Committee of GSK Plc. Philippe joined the company from Sanofi-aventis where he was President & Representative Director of sanofi-aventis Japan from 2005-2008 before being appointed Senior Vice President, Corporate Business Development Head of sanofi-aventis Group in January 2009. He served as a member of the Management Committee of sanofi-aventis Group from 2005. Philippe started his career in the pharmaceutical industry in 1984 at Hoechst Marion Roussel where he occupied, among others, various positions related to the Asia Pacific including positions in Japan and Korea from 1989-1994. He joined Sanofi-Synthelabo in 1996 and held regional positions before serving as President & Representative Director of Sanofi-Synthelabo K.K. from 2001-2004, then of sanofi-aventis K.K. until 2008. Philippe is Vice Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, a position he took up on 1 January 2014 after completing his two-year term as Chairman. He was also elected to the board of the British Chamber of Commerce in Japan (BCCJ) in April 2015, and re-elected in April 2016 and appointed French Foreign Trade Advisor (CCE) on recommendation of the Minister for Foreign Trade. Philippe is also a Board Member of JCR Pharmaceuticals Co., Ltd (4552.T) and of Japan Vaccine Co., Ltd, a joint venture between GSK and Daiichi Sankyo. He was awarded Honorary Officer of the Most Excellent Order of the British Empire (OBE) by the Queen in October 2014 and was recognized at an investiture ceremony in June 2015.

David Meeker, MD, Executive Vice President and Head of Sanofi Genzyme, Sanofi

David Meeker

David Meeker is Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi which focuses on rare diseases, multiple sclerosis, oncology, and immunology. As an Executive Vice President of Sanofi, he is a member of the Executive Committee. Dr. Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to the merger with Sanofi in 2011, Dr. Meeker was Chief Operating Officer, responsible for Genzyme’s commercial organization, overseeing its business units, country management organization and global market access functions. In October 2011 he was appointed President and Chief Executive Officer of Genzyme, a Sanofi company. Prior to joining Genzyme, Dr. Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book chapters. Dr. Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

Jingsong Wang, MD, PhD, Chief Executive Officer, Harbour BioMed

Jingsong WangDr. Jingsong Wang is the CEO of Harbour Biomed (HBM). Before founding HBM, he was the Head of China Research and Development and of Translational Medicine, Asia Pacific, for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb, where he served in multiple roles with increasing responsibilities, including Director of Discovery Medicine and Clinical Pharmacology and Global Program Lead for multiple pre-clinical and clinical assets. Dr. Wang completed his Clinical Rheumatology Fellowship and subsequently was an Attending Rheumatologist and faculty member at Brigham and Women's Hospital and Harvard Medical School. Dr. Wang received his PhD in Molecular Pharmacology from China Pharmaceutical University and has also completed a Molecular Immunology Research Fellowship at Dr. Laurie Glimcher’s laboratory at the Harvard School of Public Health. Dr. Wang is an Adjunct Assistant Professor of Medicine at the University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China, and as a scientific grant reviewer for the Medical Research Council, National Institute for Health Research, National Health Service of the United Kingdom.

Subesh Williams, Senior Vice President, Global Business Development, GlaxoSmithKline plc

Subesh WilliamsSubesh Williams is Senior Vice President, Global Corporate Development at GSK plc. Subesh is responsible for M&A and Business Development across GSK’s commercial pharmaceuticals, Consumer Healthcare and Vaccines businesses. Subesh has over seven years of experience in M&A and has been involved in executing a number of transactions, including the creation of ViiV Healthcare (a HIV JV with Pfizer and Shionogi), the 3- part deal with Novartis which involved the acquisition of Novartis’ vaccines business, the creation of a JV in Consumer Healthcare and the sale of GSK’s oncology business, the creation of a JV with Verily in bioelectronics as well as a number of other acquisitions and divestments.Subesh has a number of years of pharmaceutical experience in various roles within Finance and Corporate Development.Prior to taking on this role, Subesh was CFO of ViiVHealthcare, a joint venture between GSK , Pfizer and Shionogi. Subesh is a chartered accountant and, prior to joining GSK, was a manager at PwC.


2017年3月14日 (火)

8:00 - 8:55 朝食
8:00 - 8:55  BIO One-on-One Partnering™で設定された個別会談
9:00  - 9:20  歓迎の挨拶
9:20 - 9:55 開会全体セッション:馬場成志、厚生労働大臣政務官
10:00 - 11:55  BIO One-on-One Partnering™で設定された個別会談
10:00 - 11:55  企業プレゼンテーション
10:15 - 11:00  基調セッション:
David Meeker, MD,  Executive Vice President, Sanofi and Head, Genzyme Sanofi
11:00 - 11:45 日本での償還政策転換への対応
12:00  - 13:25  昼食会と全体セッション−討論:
13:30 - 17:55 BIO One-on-One Partnering™で設定された個別会談
13: 45 - 17:00 企業プレゼンテーション
14:00 - 14:55 神経変性疾患との闘い:アルツハイマー病などの疾患に対応する新たなモデル
15:00 - 15:55 市場展望−アジア地域での国境を越えた提携の拡大
16:00 - 16:55 アジア地域におけるベンチャーキャピタルコミュニティの拡大
18:00 - 19:30 歓迎レセプション

2017年3月15日 (水)

8:00 - 8:55 朝食
8:00 - 11:55 BIO One-on-One Partnering™で設定された個別会談
8:00 - 11:55 企業プレゼンテーション
9:00 - 9:45 日本の生物医学研究コミュニティに対して経済と患者が及ぼす影響
9:45 - 10:30 関連性の認識:環太平洋地域の業界が成長に向け取り組むべき共通の優先課題
10:45 - 11:40 国外の臨床試験パートナー獲得による承認手続きの迅速化
12:00 - 13:25 昼食会と全体セッション−討論:
Jingsong Wang, MD, PhD, Chief Executive Officer, Harbour BioMed
13:45 -14:40 アジア地域での国境を越えたトランスレーショナル研究の拡大
13:30 - 17:55 BIO One-on-One Partnering™で設定された個別会談
13:45 - 15:30 企業プレゼンテーション



  • Joseph Damond, Senior Vice President, International Affairs, Biotechnology Innovation Organization (BIO)
  • Tim Earle, Chief Operating Officer and Chief Business Officer, TauRx Pharmaceuticals Ltd
  • Carl Firth, PhD, Founder and Chief Executive Officer, Aslan Pharmaceuticals Pte. Ltd.
  • David Flores, President and Chief Executive Officer, BioCentury Inc.
  • Kyle Hathaway, PhD, Director of Policy and Government Relations, Asia Pacific, MSD
  • Benjamin Li, PhD, Chief Executive Officer, Lee's Pharmaceutical Holdings Ltd.
  • Bo Liu, PhD, Principal, Venture Investments, Johnson & Johnson Innovation - JJDC, Inc.
  • Ellen Lubman, Vice President, External Science & Innovation, Allergan PLC
  • Kevin J. Lynch, PhD, Vice President, Search and Evaluation, AbbVie
  • Christopher U. Missling, PhD, President and Chief Executive Officer, Anavex Life Sciences Corp.
  • Charles Stacey, MD, Chief Executive Officer, Accera
  • John Winebarger, President and Chief Executive Officer, Integrated Development Associates Co., Ltd.
  • Jin-San Yoo, PhD, President and Chief Executive Officer, PharmAbcine Inc.
  • Zhenping Zhu, MD, PhD, President of R&D and Chief Scientific Officer, 3SBio Inc.


















環太平洋地域では、国によって規制環境に違いがあり、研究資金調達の慣行も大きく異なっていますが、生物医学研究をリードしている国々には、バイオテクノロジー企業と新薬開発パイプラインの拡大を支えるための施策に全力で取り組んでいるという重要な共通点もあります。このセッションでは、日本、韓国、台湾、米国のバイオテクノロジー業界団体の幹部が集まり、環太平洋パートナーシップ協定 (TPP) の締結交渉が頓挫した後、各国の業界が相互に支え合い、成功を収めたプロジェクトから教訓を学び取っていくための方策について議論します。